Comparison of mortality of ESRD patients with lupus by initial dialysis modality

• Published in: Clinical journal of the American Society of Nephrology Vol. 9; no. 11; pp. 1949 - 1956
• Main Authors: Contreras, Gabriel, Pagan, Javier, Chokshi, Ruchir, Virmani, Sharad, Diego, Jorge M, Byers, Patricia, Isakova, Tamara, Munoz Mendoza, Jair, Nayer, Ali, Contreras, Jose Roberto, Panama, Gabriel, Lenz, Oliver, Carpintero, Maria, Muchayi, Timothy, Roth, David
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 07.11.2014
• Subjects: Adult; Cardiovascular Diseases - mortality; Cohort Studies; Female; Follow-Up Studies; Humans; Infection - mortality; Kidney Failure, Chronic - complications; Kidney Failure, Chronic - mortality; Kidney Failure, Chronic - therapy; Lupus Erythematosus, Systemic - complications; Lupus Erythematosus, Systemic - mortality; Male; Middle Aged; Original; Peritoneal Dialysis - mortality; Propensity Score; Renal Dialysis - methods; Renal Dialysis - mortality; Risk Assessment; Survival Rate; United States - epidemiology; United States; ESRD; mortality; SLE
• ISSN: 1555-9041; 1555-905X
• DOI: 10.2215/CJN.02500314

Little is known regarding whether mortality among ESRD patients with SLE differs between those initiating with peritoneal dialysis (PD) versus hemodialysis (HD). This study compared the mortality risk of ESRD patients with SLE initiating with PD versus HD after matching their baseline sociodemographic and clinical factors. Of 11,023 ESRD patients with SLE initiating dialysis with PD or HD between 1995 and 2006 with complete records in the US Renal Data System, 1352 pairs were matched on 13 predictors utilizing a predicted probability of group membership into the PD group using propensity score matching. The primary outcome was overall mortality. Secondary outcomes were cardiovascular-related and infection-related mortality. Outcomes were compared between groups with survival statistics. The period of observation ended on December 31, 2009. The median follow-up was 3 years. Matched pairs were predominantly women (86%) with a median age of 39 years. Matched pairs had a balance (P ≥ 0.05) of all baseline factors. Matched pairs had a similar risk of overall mortality (hazard ratio, 0.96 [95% confidence interval, 0.82 to 1.13]; mortality, 21.4% [290 to 1352] versus 22.5% [304 to 1352] for PD versus HD) within the first 3 years of observation. Matched pairs also had similar cardiovascular-related mortality (10.5% versus 9.5% for PD versus HD) and infection-related mortality (3% versus 4.4% for PD versus HD). In ESRD patients with SLE, the mortality was similar among those initiating with PD versus HD after predictors were matched between groups.